Strata Critical Medical
Strata Critical Medical's revenue rose 34.3% to $197 million in fiscal 2025. Its operating margin was −11.3%, up from −15.3% a year earlier. Free cash flow was −$59 million. The diluted share count rose 5.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Strata Critical Medical does
Strata Critical Medical, formerly Blade Air Mobility, provides time-critical transport and medical services to the U.S. healthcare industry. It flies and drives donated human organs for transplant, along with the staff and equipment that go with them. It also arranges organ placement, performs surgical organ recovery and operates devices that preserve organs before transplant. Its customers are transplant centers, organ procurement organizations, hospitals and other businesses that pay it directly.
It has two segments. Logistics, sold under the Trinity name, covers air and ground transport and organ placement. It typically charges a fixed price per flight hour, with a fuel surcharge, and mostly uses aircraft that third parties own or operate for it. Clinical, sold under the Keystone name, covers organ recovery and preservation and heart surgery support such as perfusion services, which keep blood flowing through the body during surgery. It says it competes in highly competitive markets.
In 2024 it bought ten fixed wing aircraft, which outside operators fly and maintain. As of December 31, 2025, it had 601 employees, all in the United States, including 327 full-time and 274 part-time.
Its biggest risks, as it describes them
- It has lost money since it began and may keep doing so.
- It depends on contracts with certain transplant centers, hospitals and organ procurement organizations.
- Fewer organ donors or viable donor organs would reduce demand for its services.
- Delivery failures when moving organs, and aircraft or ground accidents, could create liability and hurt its reputation.
- New technology could make ground or commercial air transport of organs more viable and cut the need for its private flights.
Income statement
From fiscal 2019 to 2025, earnings per share grew 17.5% a year and net income 61.8% a year, as new shares raised the share count by 926% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 304 | 192 | 166 | 127 | 61 |
| Debt incl. finance leases | — | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | — | −192 | −166 | −127 | −61 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −2,007.8x | — | — | — | — |
| Current ratio | 33.0x | 8.2x | 5.8x | 7.1x | 6.4x |
| Quick ratio | 33.0x | 8.2x | 5.8x | 7.1x | 6.4x |
Cash flow
Projections
Project Strata Critical Medical's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $97,840 of Strata Critical Medical shares on the open market, and 5 insiders sold $879,937, $382,267 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | Reginald LoveDirector | Sold | 5,091 | $5.75 | $29,273 | Form 4 |
| Jun 8, 2026 | William A. HeyburnCo-CEO and CFO, Director | Sold | 31,671 | $5.87 | $185,909 | Form 4 |
| Jun 8, 2026 | Melissa M. TomkielCo-CEO and General Counsel, Director | Sold | 29,730 | $5.87 | $174,515 | Form 4 |
| Jun 8, 2026 | Scott M WunschCEO, Logistics | Sold | 5,550 | $5.87 | $32,578 | Form 4 |
| Jun 8, 2026 | Amir CohenChief Accounting Officer | Sold | 4,655 | $5.87 | $27,325 | Form 4 |
| May 22, 2026 | Amir CohenChief Accounting Officer | Sold plan | 40,575 | $5.91 | $239,798 | Form 4 |
| May 21, 2026 | Amir CohenChief Accounting Officer | Sold plan | 10,300 | $5.79 | $59,637 | Form 4 |
| May 11, 2026 | Amir CohenChief Accounting Officer | Sold plan | 14,306 | $5.79 | $82,832 | Form 4 |
| Dec 9, 2025 | William A. HeyburnCo-CEO and CFO, Director | Bought | 17,000 | $4.47 | $75,990 | Form 4 |
| Dec 5, 2025 | Andrew LauckDirector | Bought | 5,000 | $4.37 | $21,850 | Form 4 |
| Nov 20, 2025 | Reginald LoveDirector | Sold | 11,000 | $4.37 | $48,070 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 4 of 9 | 4 of 9 |
| Rule of 40 | 38.8% | −57.5% | 4.6% |
| Altman Z'' | 4.54 | 7.27 | 6.54 |
| Accruals ratio | −7.7% | −9.0% | 31.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 3 of 9 | 4 of 9 | 4 of 9 |
Compare
Put Strata Critical Medical side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Strata Critical Medical | FY25 | 34.3% | −11.3% | −29.7% | −11.3% | — | 4 | |
| LifeMD | FY25 | 25.3% | −4.0% | 3.3% | — | — | — | Compare |
| biote | FY25 | −2.5% | 18.5% | 15.7% | — | 2.0x | 5 | Compare |
| SBC Medical Group | FY25 | −15.5% | 38.9% | 13.4% | 38.4% | −1.7x | 4 | Compare |
| Schrödinger | FY25 | 23.3% | −65.2% | 4.9% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | — | 50 | 146 | 225 | 147 | 197 |
| Revenue growth | — | — | — | 189.2% | 54.1% | −34.8% | 34.3% |
| Gross profit | — | — | 10 | 22 | 42 | 30 | 41 |
| Research and development | — | — | — | — | — | — | — |
| Operating income | — | −1 | −24 | −54 | −68 | −22 | −22 |
| Net income | 2 | −20 | −40 | −27 | −56 | −27 | 41 |
| Diluted EPS (US$) | 0.19 | −2.17 | −0.93 | −0.38 | −0.76 | −0.35 | 0.50 |
| Diluted shares (millions) | 8 | 10 | 43 | 71 | 74 | 78 | 82 |
| Cash flow | |||||||
| Cash from operations | — | −1 | −16 | −37 | −32 | −2 | −49 |
| Capital expenditure | — | — | 0 | 1 | 2 | 31 | 10 |
| Free cash flow | — | — | −16 | −38 | −34 | −33 | −59 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 23 | 48 | 0 | 2 | 66 |
| Stock-based compensation | — | — | 10 | 8 | 12 | 20 | 18 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 1 | 1 | 304 | 192 | 166 | 127 | 61 |
| Debt incl. finance leases | — | — | — | 0 | 0 | 0 | 0 |
| Total assets | 278 | 278 | 343 | 325 | 295 | 257 | 326 |
| Total liabilities | 26 | 47 | 52 | 50 | 61 | 35 | 46 |
| Shareholders' equity | 5 | 5 | 291 | 274 | 234 | 222 | 279 |
| Margins and ratios | |||||||
| Gross margin | — | — | 20.8% | 15.2% | 18.7% | 20.1% | 20.9% |
| Operating margin | — | — | −47.7% | −36.6% | −30.2% | −15.3% | −11.3% |
| Net margin | — | — | −79.3% | −18.7% | −24.9% | −18.6% | 21.0% |
| Free cash flow margin | — | — | −31.5% | −25.9% | −15.3% | −22.7% | −29.7% |
| Rule of 40 (growth + FCF margin) | — | — | — | 163.3% | 38.8% | −57.5% | 4.6% |
| Return on capital | — | — | — | — | −71.5% | −21.8% | −11.3% |
| Return on equity | — | — | −27.0% | −9.6% | −22.0% | −12.0% | 16.5% |
| Return on assets | — | −7.4% | −12.9% | −8.2% | −18.1% | −9.9% | 14.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — |